Can an endocytoscope system (ECS) predict histology in neoplastic lesions?

Background and study aims: An endocytoscope system (ECS) has recently been developed with the possibility of super-high magnification of gastrointestinal mucosa, thus allowing in vivo imaging of living cells. The aim of the present study was to assess the potential of ECS in the prediction of histology in both normal gastrointestinal mucosa and neoplastic lesions.

Patients and methods: In total, 76 patients (57 men, 19 women; age range 37 - 86 years) with neoplastic lesions in the esophagus, stomach, or colon were enrolled into the study and underwent esophagogastroduodenoscopy or colonoscopy. After staining with 1 % methylene blue, the mucosa was examined with the ECS probe (× 450 and × 1100 magnification), and video sequences were recorded on video disk. Biopsies from the examined areas were taken for histology and served as the gold standard. The endocytoscope video sequences were evaluated by two blinded pathologists. Finally the results were compared with those resulting from the evaluation of an experienced endoscopist who was aware of the macroscopic endoscopic pictures and the endocytoscope image results.

Results: A total of 25 patients with esophageal lesions, 28 patients with colonic lesions, and 23 patients with gastric lesions were examined. The sensitivity and specificity for the evaluation of the blinded pathologists was 81 % and 100 %, respectively, in the esophagus, 56 % and 89 % in the stomach, and 79 % and 90 % in the colon. If an endoscopist evaluated the endocytoscopic pictures in combination with the macroscopic endoscopic images sensitivity and specificity increased significantly.

Conclusions: First experiences with ECS show good sensitivity rates even by blinded assessment for esophageal and colonic lesions. Sensitivity for neoplastic lesions in the stomach is lower because of gastric mucous secretion. Combining the endoscopic and cytoscopic appearance of the lesion may further enhance the diagnostic value of the method.

References

• 1 Sharma P, Topalovski M, Mayo M, Weston A. Methylene blue chromoendoscopy for detection of short-segment Barrett’s esophagus.  Gastrointest Endosc. 2001;  54 289-293
• 2 Muto M, Hironaka S, Nakane M. et al . Association of multiple Lugol-voiding lesions with synchronous and metachronous esophageal squamous cell carcinoma in patients with head and neck cancer.  Gastrointest Endosc. 2002;  56 517-521
• 3 Kudo S, Tamura S, Nakajima T. et al . Diagnosis of colorectal tumorous lesions by magnifying endoscopy.  Gastrointest Endosc. 1996;  44 8-14
• 4 Messmann H, Endlicher E, Freunek G. et al . Fluorescence endoscopy for the detection of low and high grade dysplasia in ulcerative colitis using systemic or local 5-aminolaevulinic acid sensitisation.  Gut. 2003;  52 1003-1007
• 5 Georgakoudi I, Feld M S. The combined use of fluorescence, reflectance, and light scattering spectroscopy for evaluating dysplasia in Barrett’s esophagus.  Gastrointest Endosc Clin N Am. 2004;  14 519-537
• 6 Kiesslich R, Burg J, Vieth M. et al . Confocal laser endoscopy for diagnosing intraepithelial neoplasias and colorectal cancer in vivo.  Gastroenterology. 2004;  127 706-713
• 7 Kumagai Y, Moma K, Kawada K. Magnifying chromoendoscopy of the esophagus: in-vivo pathological diagnosis using an endocytoscopy system.  Endoscopy. 2004;  36 290-294
• 8 Inoue H, Kazawa T, Sato Y. et al . In vivo observation of living cancer cells in the esophagus, stomach, and colon using catheter-type contact endoscope, “Endo-cytoscopy system”.  Gastrointest Endosc Clin N Am. 2004;  14 589-594
• 9 Kiesslich R, Jung M, DiSario J A. et al . Perspectives of chromo and magnifying endoscopy: how, how much, when, and whom should we stain?.  J Clin Gastroenterol. 2004;  38 7-13
• 10 Canto M I. Methylene blue chromoendoscopy for Barrett’s esophagus: coming soon to your GI unit?.  Gastrointest Endosc. 2001;  54 560-568